Spots Global Cancer Trial Database for A Long-term Follow-up Study of Patients Who Received VOR33
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Long-term Follow-up Study of Patients Who Received VOR33
Official Title: A Long-term Follow-up Study of Patients Who Received VOR33
Study ID: NCT05309733
Conditions
Interventions
Study Description
Brief Summary: VOR33 long-term follow-up (LTFU) study
Detailed Description: VBP201 study is the VOR33 long-term follow-up (LTFU) study focusing on assessing long term safety and efficacy of VOR33. This study may last up to 15 years (counted from the date of VOR33 infusion completion). All patients who have participated in a study involving the drug product VOR33 and have completed the applicable study or prematurely discontinued, but have at least received the VOR33 infusion, will be asked to participate in the LTFU study.
Eligibility
Minimum Age:
Eligible Ages: CHILD, ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
University of California San Diego Moores Cancer Center, La Jolla, California, United States
Miami Cancer Institute, Miami, Florida, United States
National Institutes of Health, Clinical Center, Bethesda, Maryland, United States
Washington University School of Medicine Siteman Cancer Center, Saint Louis, Missouri, United States
John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States
Columbia University Medical Center - Herbert Irving Comprehensive Cancer Center, New York, New York, United States
Memorial Sloan Kettering Cancer Center, New York, New York, United States
University Hospitals Seidman Cancer Center, Cleveland, Ohio, United States
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
Hôpital Maisonneuve-Rosemont, Montréal, Quebec, Canada
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
